| Day 1 | Day 14 | |||||
---|---|---|---|---|---|---|---|
Adjusted geometric mean | Adjusted geometric mean ratio (90% CI) (Japanese/Caucasian) | Adjusted geometric mean | Adjusted geometric mean ratio (90% CI) (Japanese/Caucasian) | ||||
Treatment | PK parameter (unit) | Japanese | Caucasian | Japanese | Caucasian | ||
Analyte: indacaterol | |||||||
 IND/GLY/MF high-dose | Cmax (pg/mL) | 327 (n = 13) | 269 (n = 15) | 1.22 (1.05, 1.41) | 586 (n = 14) | 447 (n = 15) | 1.31 (1.13, 1.51) |
AUC0–24 h (h × pg/mL) | 989 (n = 13) | 877 (n = 15) | 1.13 (0.971, 1.31) | 3190 (n = 14) | 2730 (n = 15) | 1.17 (1.01, 1.35) | |
 IND/GLY/MF medium-dose | Cmax (pg/mL) | 374 (n = 15) | 263 (n = 16) | 1.42 (1.24, 1.63) | 578 (n = 16) | 446 (n = 16) | 1.30 (1.13, 1.49) |
AUC0–24 h (h × pg/mL) | 1070 (n = 15) | 836 (n = 16) | 1.28 (1.11, 1.48) | 3250 (n = 16) | 2680 (n = 16) | 1.21 (1.05, 1.40) | |
Analyte: glycopyrronium | |||||||
 IND/GLY/MF high-dose | Cmax (pg/mL) | 267 (n = 14) | 185 (n = 15) | 1.45 (1.16, 1.81) | 424 (n = 14) | 308 (n = 15) | 1.38 (1.13, 1.69) |
AUC0–24 h (h × pg/mL) | 270 (n = 14) | 263 (n = 15) | 1.02 (0.860, 1.22) | 739 (n = 14) | 702 (n = 15) | 1.05 (0.920, 1.20) | |
 IND/GLY/MF medium-dose | Cmax (pg/mL) | 279 (n = 16) | 185 (n = 16) | 1.51 (1.22, 1.87) | 437 (n = 16) | 284 (n = 16) | 1.54 (1.27, 1.87) |
AUC0–24 h (h × pg/mL) | 285 (n = 16) | 260 (n = 16) | 1.10 (0.925, 1.30) | 755 (n = 16) | 712 (n = 16) | 1.06 (0.929, 1.21) | |
Analyte: mometasone furoate | |||||||
 IND/GLY/MF high-dose | Cmax (pg/mL) | 195 (n = 14) | 193 (n = 15) | 1.01 (0.920, 1.11) | 264 (n = 14) | 247 (n = 15) | 1.07 (0.969, 1.18) |
AUC0–24 h (h × pg/mL) | 1700 (n = 14) | 1600 (n = 15) | 1.07 (0.964, 1.18) | 2520 (n = 14) | 2180 (n = 15) | 1.15 (1.05, 1.27) | |
 IND/GLY/MF medium-dose | Cmax (pg/mL) | 104 (n = 16) | 96.3 (n = 16) | 1.08 (0.990, 1.18) | 139 (n = 16) | 121 (n = 16) | 1.15 (1.04, 1.26) |
AUC0–24 h (h × pg/mL) | 926 (n = 16) | 784 (n = 16) | 1.18 (1.07, 1.30) | 1260 (n = 16) | 1030 (n = 16) | 1.23 (1.12, 1.34) |